]> 2026-07-31T10:04:37+00:00 WBR0481 0 en Prevention of LDL receptor degradation in the lysosomes Correct – LDL receptors function in the removal of cholesterol from the plasma. Agents that can preserve these receptors will indirectly increase the removal of LDL cholesterol from the plasma Promotes the activity of HMG-CoA reductase Inhibits cholesterol ester transfer protein Blocks cholesterol absorption at the brush border of small intestine Promotes the degradation of LDL receptors Incorrect – Any drug which promotes the degradation of LDL receptors indirectly prevents the removal of cholesterol from the plasma, thereby leading to hypercholesterolemia Internal medicine In a quest to find the ultimate low density liproprotein cholesterol (LDL-C) lowering drug for the treatment of heterozygous familial hypercholesterolemia, researchers have discovered an endogenous substance, Proprotein convertase subtilisin/kexin type 9 (PCSK9), which acts by binding to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR). It was also postulated that developing monoclonal antibodies against this compound will have a tremendous effect in lowering the level of LDL-cholesterol in this group of patients. Which of the following mechanisms of action best describes this experimental drug? A 2020-10-28T00:43:04Z 2459150.5299074 WBR0481